Skip to main content

Table 3 24 h incubation half inhibitory effect (IC50) of the free and nano-RX regimens and their cytotoxic and IC50 fold changes

From: Hyaluronated nanoparticles deliver raloxifene to CD44-expressed colon cancer cells and regulate lncRNAs/miRNAs epigenetic cascade

Parameters

Cell lines

Free and nano-regimens

RX

RX-CS NPs (F1)

RX-CS NPs (F2)

RX-HA-CS NPs

IC50, µM

Caco-2 cells

64.07

56.31

61.06

25.45

HCT 116 cells

86.79

45.59

54.10

40.22

WI-38 cells

76.30

ND

ND

ND

Cytotoxic fold

Caco-2 cells

Ref.

1.14

1.05

2.52

HCT 116 cells

Ref.

1.90

1.60

2.16

WI-38 cells

Ref.

0.76

0.76

0.76

IC50 fold

Caco-2 cells

Ref.

0.88

0.95

0.40

HCT 116 cells

Ref.

0.53

0.62

0.46

WI-38 cells

Ref.

ND

ND

ND

  1. The cytotoxic fold change represents the IC50 of the free RX divided by the IC50 of each nano-platform to calculate the cytotoxic fold change between the RX-encapsulated nanoparticles versus the free counterpart (RX). The IC50 fold change represents the IC50 of each nano-platform divided by free RX to calculate the fold times in IC50 values between the RX-encapsulated nanoparticles compared to the free counterpart (RX)
  2. Caco-2 and HCT 116 cells: human colorectal cell lines, IC50 the average of colorectal cancer cell’s half inhibitory effect; RX raloxifene, HA hyaluronic acid, CS: chitosan, NPs nanoparticles